This review provides a balanced perspective on the use of intravenous pharmacologic agents for managing specific challenges in neuroanesthesia.
Caution against routine adoption in neuroanesthesia; leaves open optimal agent selection pending higher-level evidence.
No takes yet. Share an insight, caveat, or question.
David J. Stone (2000) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: